Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights

Biotech SG&A Expenses: Madrigal vs. Opthea

__timestampMadrigal Pharmaceuticals, Inc.Opthea Limited
Wednesday, January 1, 2014157460002652041
Thursday, January 1, 2015133920002361587
Friday, January 1, 201692900004472869
Sunday, January 1, 201776720005030957
Monday, January 1, 2018152930004988941
Tuesday, January 1, 2019226480005196412
Wednesday, January 1, 2020218640006652774
Friday, January 1, 20213731800018418247
Saturday, January 1, 20224813000024827066
Sunday, January 1, 202310814600041896408
Monday, January 1, 202415488619
Loading chart...

Igniting the spark of knowledge

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Madrigal Pharmaceuticals, Inc. and Opthea Limited from 2014 to 2023. Over this period, Madrigal Pharmaceuticals has seen a dramatic increase in SG&A expenses, rising by approximately 587% from 2014 to 2023. In contrast, Opthea Limited's expenses grew by about 1,480% during the same period, albeit from a smaller base. Notably, Madrigal's expenses peaked in 2023, reaching nearly 2.6 times their 2022 value, while Opthea's expenses also saw a significant jump, more than doubling from 2021 to 2022. These trends highlight the differing strategies and growth trajectories of these two companies in the biotech sector. Missing data for 2024 suggests a need for further updates to maintain accurate insights.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025